# AI Financial Corp: Form 10-Q/A for the period ended Oct 1, 2022

- Company: [AI Financial Corp](/companies/aifc.md) (CIK 862861)
- Form: 10-Q/A
- Filed: 2023-04-25
- Accepted by EDGAR: Apr 25, 2023, 17:01 ET
- Period: 2022-10-01
- Accession: 0000950170-23-014500
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/862861/000095017023014500/jan-20221001.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/862861/000095017023014500/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-10-01.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-03 to 2022-10-01 | $8.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-02 to 2022-10-01 | $28.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2022-07-03 to 2022-10-01 | $1.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-02 to 2022-10-01 | $4.5m | us-gaap:GrossProfit |
| Income tax | 9 months, 2022-01-02 to 2022-10-01 | $23.0k | us-gaap:IncomeTaxExpenseBenefit |
| Current assets | at 2022-10-01 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | at 2022-10-01 | $29.6m | us-gaap:Assets |
| Long-term debt | at 2022-10-01 | $1.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-10-01 | $4.1m | us-gaap:LongTermDebtCurrent |

## Management's discussion and analysis

As filed, 27,441 characters.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per–share amounts.

### Forward-Looking and Cautionary Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Form 10-K and Part II, Item 1A of this Form 10-Q. Some of the factors that we believe could affect our results include:

- the continued effect on the U.S. economy of the coronavirus public health crisis;
- our ability to secure additional financing to execute our biotechnology business plan;
- our ability to obtain the marketing approval for JAN101, our initial drug product candidate;
- the effect that the SEC Complaint has on the Company, if any;
- the strength of energy conservation recycling programs;
- our continued ability to purchase product from our suppliers at acceptable prices;
- costs and expenses being realized at higher-than-expected levels;
- our ability to secure an adequate supply of special-buy appliances for resale;
- the ability to secure appliance recycling and replacement contracts with sponsors of energy efficiency programs;
- the ability of customers to supply units under their recycling contracts with us;
- the outcome of the sales and use tax examination in California; and
- general economic conditions affecting consumer demand for appliances.

We caution you that the foregoing list of important factors may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this Quarterly Report on Form 10-Q may not in fact occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Our MD&A should be read in conjunction with our Form 10-K (including the information presented therein under the caption *Risk Factors*), together with our Quarterly Reports on Forms 10-Q and other publicly available information. All amounts herein are unaudited.

### Overview

We are focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. In addition, through our subsidiaries ARCA Recycling, Connexx, and ARCA Canada, we are engaged in the business of recycling major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Also, through our GeoTraq Inc. subsidiary, we have been engaged in the development, design of wireless transceiver modules with technology that provides LBS directly from global Mobile IoT networks. However, Our GeoTraq subsidiary has not generated any revenue to date, including in the fiscal year ended January 1, 2022. Consequently, during the year ended January 1, 2022, the Company took a full write-down of the unamortized portion of the GeoTraq intangible asset of approximately $9.8 million. Further, the gain associated with the GeoTraq disposition (Technology segment) has been restated and presented as discontinued operations for the periods ending October 1, 2022. As such, the results of the Technology segment have been reclassified and presented as discontinued operations for the periods ending October 2, 2021.

We operate three reportable segments:

- Biotechnology: Our biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
- Recycling: Our recycling segment is a turnkey appliance recycling program. We receive fees charged for recycling, replacement and additional services for utility energy efficiency programs and have established 18 Regional Processing Centers (“RPCs”) for this segment throughout the United States and Canada.
- Technology: We have suspended all operations for GeoTraq, and, on May 24, 2022, sold substantially all of the GeoTraq assets. Further, the gain associated with the GeoTraq disposition (Technology segment) has been restated and presented as discontinued operations for the periods ending October 1, 2022. As such, the results of the Technology segment have been reclassified and presented as discontinued operations for the periods ending October 2, 2021.

### For the 13 weeks ended October 1, 2022 and October 2, 2021

### Results of Operations (Restated)

The following table sets forth certain statement of operations items and as a percentage of revenue, as restated, for the periods indicated (in $000's):

| Statement of Operations Data: | 13 Weeks Ended October 1, 2022 (As restated) |  | 13 Weeks Ended October 2, 2021 |  |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $8,587 | 100.0% | $12,113 | 100.0% |
| Cost of revenue | 7,553 | 88.0% | 9,032 | 74.6% |
| Gross profit | 1,034 | 12.0% | 3,081 | 25.4% |
| Selling, general and administrative expense | 2,858 | 33.3% | 2,989 | 24.7% |
| Gain on sale of GeoTraq | — | 0.0% | — | 0.0% |
| Operating loss | (1,824) | -21.2% | 92 | 0.8% |
| Interest income (expense), net | 130 | 1.5% | (125) | -1.0% |
| Gain on settlement of vendor advance payments | — | 0.0% | 11 | 0.1% |
| Unrealized loss on marketable securities | (270) | -3.1% | — | 0.0% |
| Other income | — | 0.0% | 23 | 0.2% |
| Net loss from continuing operations before provision for income taxes | (1,964) | -22.9% | 1 | 0.0% |
| Provision for income taxes | 16 | 0.2% | 33 | 0.3% |
| Net loss from continuing operations | (1,980) | -23.1% | (32) | -0.3% |
| Income (loss) from discontinued operations, net of tax | (1) | 0.0% | (936) | -7.7% |
| Net loss | $(1,981) | -23.1% | $(968) | -8.0% |

34

The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000's):

| Revenue | 13 Weeks Ended October 1, 2022 Net Revenue | Percent of Total | 13 Weeks Ended October 2, 2021 Net Revenue | Percent of Total |
| --- | ---: | ---: | ---: | ---: |
| Recycling and Byproducts | $6,334 | 73.8% | $6,714 | 55.4% |
| Replacement Appliances | 2,253 | 26.2% | 5,399 | 44.6% |
| Total Revenue | $8,587 | 100.0% | $12,113 | 100.0% |

| Gross Profit | 13 Weeks Ended October 1, 2022 Gross Profit | Gross Profit % | 13 Weeks Ended October 2, 2021 Gross Profit | Gross Profit % |
| --- | ---: | ---: | ---: | ---: |
| Recycling and Byproducts | $200 | 3.2% | $1,277 | 19.0% |
| Replacement Appliances | 834 | 37.0% | 1,804 | 33.4% |
| Total Gross Profit | $1,034 | 12.0% | $3,081 | 25.4% |

### Revenue

Revenue decreased by approximately $3.5 million, or 29.1%, for the 13 weeks ended October 1, 2022, as compared to the 13 weeks ended October 2, 2021. The decrease is primarily due to reduced replacement volume due to a lack of appliance availability, and weakening commodity markets, partially offset by increased recycling volume.

### Cost of Revenue

Cost of revenue decreased by approximately $1.5 million, or 16.4%, for the 13 weeks ended October 1, 2022, as compared to the 13 weeks ended October 2, 2021, due to the factors described above.

### Selling, General and Administrative Expense (Restated)

Selling, general and administrative expense decreased by approximately $131,000, or 4.4%, for the 13 weeks ended October 1, 2022, as compared to the 13 weeks ended October 2, 2021, primarily due to decreases in stock-based compensation, professional fees, amortization expense, and legal fees.

### Interest Expense, net

Interest expense, net, decreased by approximately $255,000 for the 13 weeks ended October 1, 2022, as compared to the 13 weeks ended October 2, 2021 primarily due to interest income recorded in connection with the sale of GeoTraq.

### Unrealized Loss on Marketable Securities

For the 13 weeks ended October 1, 2022, an unrealized loss on marketable securities of approximately $270,000 was recorded to mark to fair value securities received in connection to the sale of GeoTraq. See Note 25 of the unaudited Consolidated Financial Statements. There were no similar transactions for the 13 weeks ended October 2, 2021.

### Gain on Settlement of Vendor Advance Payments

For the 13 weeks ended October 2, 2021, a portion of the vendor advance payments were settled, which resulted in a gain of approximately $11,000. There were no similar transactions for the 13 weeks ended October 1, 2022.

### Segment Performance (Restated)

We report our business in the following segments: Biotechnology, Recycling, and Technology. We identified these segments based on a combination of business type, customers serviced and how we divide management responsibility. Our revenues and profits are driven through our recycling centers, e-commerce, individual sales reps and our internet services for our recycling and technology segment. We expect revenues and profits for our biotechnology segment to be driven by the development of pharmaceuticals that treat the root cause of pain but are non-opioid painkillers. We include corporate expenses within the Recycling segment.

Operating loss by operating segment, is defined as loss before net interest expense, other income and expense, provision for income taxes ($000’s):

|  | 13 Weeks Ended October 1, 2022 (As restated) Biotechnology | Recycling | Continuing Operations | Discontinued Operations | Total | 13 Weeks Ended October 2, 2021 Biotechnology | Recycling | Continuing Operations | Discontinued Operations | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $— | $8,587 | $8,587 | $— | $8,587 | $— | $12,113 | $12,113 | $— | $12,113 |
| Cost of revenue | — | 7,553 | 7,553 | — | 7,553 | — | 9,032 | 9,032 | — | 9,032 |
| Gross profit | — | 1,034 | 1,034 | — | 1,034 | — | 3,081 | 3,081 | — | 3,081 |
| Selling, general and administrative expense | (21) | 2,879 | 2,858 | 1 | 2,859 | 182 | 2,807 | 2,989 | 936 | 3,925 |
| Operating income (loss) | $21 | $(1,845) | $(1,824) | $(1) | $(1,825) | $(182) | $274 | $92 | $(936) | $(844) |

### Biotechnology Segment

Our biotechnology segment incurred expenses of approximately $124,000, offset by a gain of approximately $145,000 due to an overstatement of segment expenses in Q2 2022 for the 13 weeks ended October 1, 2022, and $182,000 related to employee costs and professional services related to research for the 13 weeks ended October 2, 2021.

### Recycling Segment

The recycling segment consists of ARCA Recycling, Customer Connexx, and ARCA Canada. Revenue for the 13 weeks ended October 1, 2022, decreased by approximately $3.5 million, or 29.1%, as compared to the prior year period. Replacement services revenue decreased by approximately $3.1 million, period over period, primarily due to reduced replacement volume due to a lack of appliance availability. Recycling and Byproducts revenue decreased by approximately $380,000 primarily due to weakening commodity markets.

Cost of revenue for the 13 weeks ended October 1, 2022, decreased by approximately $1.5 million, or 16.4%, as compared to the prior year period, for those reasons described above.

Operating loss for the 13 weeks ended October 1, 2022, increased by approximately $2.1 million, as compared to the prior year period. The increase is due to an decrease in gross profit of approximately $2.0 million, partially offset by an increase in selling, general and administrative expenses of approximately $72,000.

### Discontinued Operations (Restated)

Discontinued operations consists of GeoTraq. There was no activity from discontinued operations for the 13 weeks ended October 1, 2022 due to the sale of GeoTraq during the period ended July 2, 2022. See Note 25 of the unaudited Consolidated Financial Statements. Further, the gain associated with the GeoTraq disposition (Technology segment) has been restated and presented as discontinued operations for the periods ending October 1, 2022. As such, the results of the Technology segment have been reclassified and presented as discontinued operations for the periods ending October 2, 2021.

### For the 39 weeks ended October 1, 2022 and October 2, 2021

### Results of Operations (Restated)

The following table sets forth certain statement of operations items and as a percentage of revenue, for the periods indicated (in $000's):

| Statement of Operations Data: | 39 Weeks Ended October 1, 2022 (As restated) |  | 39 Weeks Ended October 2, 2021 |  |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $28,449 | 100.0% | $29,391 | 100.0% |
| Cost of revenue | 23,913 | 84.1% | 23,146 | 78.8% |
| Gross profit | 4,536 | 15.9% | 6,245 | 21.2% |
| Selling, general and administrative expense | 8,705 | 30.6% | 9,230 | 31.4% |
| Gain on sale of GeoTraq | — | 0.0% | — | 0.0% |
| Operating income (loss) | (4,169) | -14.7% | (2,985) | -10.2% |
| Interest expense, net | (123) | -0.4% | (323) | -1.1% |
| Gain on Payroll Protection Program loan forgiveness | — | 0.0% | 1,872 | 6.4% |
| Gain on settlement of vendor advance payments | — | 0.0% | 952 | 3.2% |
| Gain (loss) on litigation settlement, net | 1,835 | 6.5% | (1,950) | -6.6% |
| Gain on reversal of contingency loss | 637 | 2.2% | — | 0.0% |
| Unrealized loss on marketable securities | (646) | -2.3% | — | 0.0% |
| Other income, net | 359 | 1.3% | 45 | 0.2% |
| Net loss from continuing operations before provision for income taxes | (2,107) | -7.4% | (2,389) | -8.1% |
| Provision for income taxes | 23 | 0.1% | 236 | 0.8% |
| Net loss from continuing operations | (2,130) | -7.5% | (2,625) | -8.9% |
| Income (loss) from discontinued operations, net of tax | 10,234 | 36.0% | (2,820) | -9.6% |
| Net income (loss) | $8,104 | 28.5% | $(5,445) | -18.5% |

The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000's):

| Revenue | 39 Weeks Ended October 1, 2022 Net Revenue | Percent of Total | 39 Weeks Ended October 2, 2021 Net Revenue | Percent of Total |
| --- | ---: | ---: | ---: | ---: |
| Recycling and Byproducts | $15,850 | 55.7% | $15,580 | 53.0% |
| Replacement Appliances | 12,599 | 44.3% | 13,811 | 47.0% |
| Total Revenue | $28,449 | 100.0% | $29,391 | 100.0% |

| Gross Profit | 39 Weeks Ended October 1, 2022 Gross Profit | Gross Profit % | 39 Weeks Ended October 2, 2021 Gross Profit | Gross Profit % |
| --- | ---: | ---: | ---: | ---: |
| Recycling and Byproducts | $68 | 0.4% | $1,739 | 11.2% |
| Replacement Appliances | 4,468 | 35.5% | 4,506 | 32.6% |
| Total Gross Profit | $4,536 | 15.9% | $6,245 | 21.2% |

### Revenue

Revenue decreased by approximately $940,000, or 3.2%, for the 39 weeks ended October 1, 2022, as compared to the 39 weeks ended October 2, 2021. The decrease is primarily due to reduced replacement volume due to a lack of appliance availability, and weakening commodity markets, partially offset by increased recycling volume.

### Cost of Revenue

Cost of revenue increased by approximately $765,000, or 3.3%, for the 39 weeks ended October 1, 2022, as compared to the 39 weeks ended October 2, 2021, due to the factors described above.

### Selling, General and Administrative Expense (Restated)

Selling, general and administrative expense decreased by approximately $525,000, or 5.7%, for the 39 weeks ended October 1, 2022, as compared to the 39 weeks ended October 2, 2021, primarily due to decreases in stock-based compensation, professional fees, amortization expense, and legal fees.

### Interest Expense, net (Restated)

Interest expense, net, decreased by approximately $200,000 for the 39 weeks ended October 1, 2022, as compared to the 39 weeks ended October 2, 2021 primarily due to interest income recorded in connection with the sale of GeoTraq, partially offset by increased interest on notes payable.

### Gain on Sale of GeoTraq (Restated)

During the 39 weeks ended October 1, 2022, we recorded a gain on the sale of GeoTraq of approximately $10.2 million. See Note 25 of unaudited Condensed Consolidated Financial Statements. Further, the gain associated with the GeoTraq disposition (Technology segment) has been restated and presented as discontinued operations for the periods ending October 1, 2022. As such, the results of the Technology segment have been reclassified and presented as discontinued operations for the periods ending October 2, 2021.

### Unrealized Loss on Marketable Securities

For the 39 weeks ended October 1, 2022, an unrealized loss on marketable securities of approximately $646,000 was recorded to mark to fair value securities received in connection to the sale of GeoTraq. See Note 25 of unaudited Consolidated Financial Statements. There were no similar transactions for the 39 weeks ended October 2, 2021.

### Gain on Litigation Settlement, net

Gain on litigation settlement includes the receipt of a $1.95 million payment from Sompo International Companies (“Sompo”) in exchange for a full release in favor of Sampo from liability for both the GeoTraq and SEC-related matters, partially offset by an accrual of approximately $115,000 to finalize the Blackhawk settlement.

### Gain on Reversal of Contingency Loss

Gain on reversal of continency loss reverses approximately $637,000 in contingent liabilities relating to guarantees of ApplianceSmart leases that no longer exist as a result of ApplianceSmart's emergence from bankruptcy (see Notes 7 to the unaudited financial statements).

### Gain on Settlement of Vendor Advance Payments

For the 39 weeks ended October 2, 2021, a portion of the vendor advance payments were settled, which resulted in a gain of approximately $952,000. There were no similar transactions for the 39 weeks ended October 1, 2022.

### Segment Performance (Restated)

We report our business in the following segments: Biotechnology, Recycling, and Technology. We identified these segments based on a combination of business type, customers serviced and how we divide management responsibility. Our revenues and profits are driven through our recycling centers, e-commerce, individual sales reps and our internet services for our recycling and technology segment.

We expect revenues and profits for our biotechnology segment to be driven by the development of pharmaceuticals that treat the root cause of pain but are non-opioid painkillers. We include corporate expenses within the Recycling segment.

Operating loss by operating segment, is defined as loss before net interest expense, other income and expense, provision for income taxes ($000’s):

|  | 39 Weeks Ended October 1, 2022 (As restated) Biotechnology | Recycling | Continuing Operations | Discontinued Operations | Total | 39 Weeks Ended October 2, 2021 Biotechnology | Recycling | Continuing Operations | Discontinued Operations | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $— | $28,449 | $28,449 | $— | $28,449 | $— | $29,391 | $29,391 | $— | $29,391 |
| Cost of revenue | — | 23,913 | 23,913 | — | 23,913 | — | 23,146 | 23,146 | — | 23,146 |
| Gross profit | — | 4,536 | 4,536 | — | 4,536 | — | 6,245 | 6,245 | — | 6,245 |
| Selling, general and administrative expense | 331 | 8,374 | 8,705 | (10,234) | (1,529) | 1,232 | 7,998 | 9,230 | 2,820 | 12,050 |
| Operating income (loss) | $(331) | $(3,838) | $(4,169) | $10,234 | $6,065 | $(1,232) | $(1,753) | $(2,985) | $(2,820) | $(5,805) |

### Biotechnology Segment

Our biotechnology segment incurred expenses of approximately $331,000 and $1.2 million related to employee costs and professional services related to research for the 39 weeks ended October 1, 2022 and October 2, 2021, respectively.

### Recycling Segment

The recycling segment consists of ARCA Recycling, Customer Connexx, and ARCA Canada. Revenue for the 39 weeks ended October 1, 2022, decreased by approximately $940,000, or 3.2%, as compared to the prior year period. Replacement services revenue decreased by approximately $1.2 million, period over period, primarily due to reduced replacement volume due to a lack of appliance availability. Recycling and Byproducts revenue increased by approximately $270,000 primarily due to strong consumer demand, partially offset by weakening commodity markets.

Cost of revenue for the 39 weeks ended October 1, 2022, increased by approximately $765,000, or 3.3%, as compared to the prior year period, for those reasons described above.

Operating loss for the 39 weeks ended October 1, 2022, increased by approximately $2.1 million as compared to the prior year period. The increase is due to an decrease in gross profit of approximately $1.7 million, and an increase in selling, general and administrative expenses of approximately $400,000.

### Discontinued Operations

Discontinued operations consists of GeoTraq. Results for the 39 weeks ended October 1, 2022 includes income of approximately $10.2 million, as compared to a loss of approximately $2.8 million for the 39 weeks ended October 2, 2021. The increase is due to the gain on sale of GeoTraq. Further, the gain associated with the GeoTraq disposition (Technology segment) has been restated and presented as discontinued operations for the periods ending October 1, 2022. As such, the results of the Technology segment have been reclassified and presented as discontinued operations for the periods ending October 2, 2021.

### Liquidity and Capital Resources

#### Overview

As of October 1, 2022, we had total cash on hand of approximately $868. As we continue to prepare to begin late-stage clinical development with our pharmaceutical product, JAN101, and potentially pursue strategic transactions to expand and grow our business, we regularly monitor capital market conditions and may raise additional funds through borrowings or public or private sales of debt or equity securities. The amount, nature and timing of any borrowings or sales of debt or equity securities will depend on our operating performance and other circumstances; our then-current commitments and obligations; the amount, nature and timing of our capital requirements; any limitations imposed by our current credit arrangements; and overall market conditions.

Based on our current operating plans, we believe that available cash balances, funds available under our credit facility with Gulf Coast, and or other refinancing of existing indebtedness will provide sufficient liquidity to fund our operations, our continued investments in store openings and remodeling activities for at least the next 12 months.

#### Cash Flows

During the 39 weeks ended October 1, 2022, cash used in operations was approximately $2.4 million, compared to cash used in operations of approximately $3.5 million during the 39 weeks ended October 2, 2021. The increase in cash used in operations was primarily due to results of operations, as discussed above.

Cash used in investing activities was approximately $950,000 and $1.6 million, respectively, for the 39 weeks ended October 1, 2022 and the 39 weeks ended October 2, 2021, primarily related to purchases of property and equipment and intangibles.

Cash provided by financing activities was approximately $3.5 million for the 39 weeks ended October 1, 2022, and was primarily due to the proceeds from the new credit facility, as discussed in Note 16 above. Cash provided by financing activities was approximately $7.6 million for the 39 weeks ended October 2, 2021 primarily due to net proceeds received from an equity financing in the amount approximately $5.5 million.

#### Sources of Liquidity

We utilize cash on hand and factor certain accounts receivable invoices to cover normal and seasonal fluctuations in cash flows and to support our various growth initiatives. Our cash and cash equivalents are carried at cost and consist primarily of demand deposits with commercial banks. On September 26, 2022, the Company entered into a credit facility with Gulf Coast, whereby the Company can obtain financing up to the lesser of $7.0 million or its calculated borrowing base. Gulf Coast has been granted a security interest in substantially all of ARCA Recycling’s assets. The current purchase and sale agreement with Gulf Coast automatically renews every two years unless terminated by the parties.

We acknowledge that we continue to face a challenging competitive environment as we continue to focus on our overall profitability, including managing expenses. We reported net income of approximately $8.1 million and a net loss of approximately $5.4 million, respectively, for the 39 weeks ended October 1, 2022 and October 2, 2021. In addition, the Company has total current assets of approximately $9.4 million and total current liabilities of approximately $23.8 million resulting in a net negative working capital of approximately $14.5 million as of October 1, 2022.

Based on the above, management has concluded that the Company is not aware and did not identify any other conditions or events that would cause the Company to not be able to continue business as a going concern for the next twelve months

#### Future Sources of Cash; Phase 2b Trials, New Acquisitions, Products, and Services

We may require additional debt financing and/or capital to finance new acquisitions, refinance existing indebtedness, conduct our Phase IIb clinical trials, or consummate other strategic investments in our business. Any financing obtained may further dilute or otherwise impair the ownership interest of our existing stockholders.

## Market risk

As filed, 937 characters.

### Market Risk and Impact of Inflation

*Interest Rate Risk*. We do not believe there is any significant risk related to interest rate fluctuations on our short and long-term fixed rate debt.

*Foreign Currency Exchange Rate Risk*. We currently generate revenues in Canada. The reporting currency for our consolidated financial statements is U.S. dollars. It is not possible to determine the exact impact of foreign currency exchange rate changes; however, the effect on reported revenue and net earnings can be estimated. We estimate that the overall strength of the U.S. dollar against the Canadian dollar had an immaterial impact on the revenues and net income for the fiscal year ended January 1, 2022. We do not currently hedge foreign currency fluctuations and do not intend to do so for the foreseeable future.

We do not hold any derivative financial instruments, nor do we hold any securities for trading or speculative purposes.

## Controls and procedures

As filed, 5,158 characters.

### Evaluation of Disclosure Controls and Procedures

Evaluation of Disclosure Control and Procedures. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer (our CEO) and principal financial officer (our CFO), of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of October 1, 2022, the period covered in this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting during the quarter ended October 1, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of October 1, 2022. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in 2013 regarding Internal Control – Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal control over financial reporting was not effective as of October 1, 2022.

Management noted material weaknesses in internal control when conducting their evaluation of internal control as of October 1, 2022. (1) Insufficient information technology general controls (“ITGC”) and segregation of duties. It was noted that people who were negotiating a contract, were also involved in approving invoices without proper oversight. Additional controls and procedures are necessary and are being implemented to have check and balance on significant transactions and governance with those charged with governance authority. (2) Inadequate control design or lack of sufficient controls over significant accounting processes. The cutoff and reconciliation procedures were not effective with certain accrued and deferred expenses. (3) Insufficient assessment of the impact of potentially significant transactions, and (4) Insufficient processes and procedures related to proper recordkeeping of agreements and contracts. In addition, contract to invoice reconciliation was not effective with certain transportation service providers. As part of its remediation plan, processes and procedures have been implemented to help ensure accruals and invoices are reviewed for accuracy and properly recorded in the appropriate period. These material weaknesses remained outstanding as of the filing date of this quarterly report on Form 10-Q and management is currently working to remedy these outstanding material weaknesses.

The Company’s management, including the Company’s CEO and CFO, do not expect that the Company’s disclosure controls and procedures or the Company’s internal control over financial reporting will prevent or detect all error and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgements in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override, the design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

## Risk factors

As filed, 3,829 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. However, in light of the SEC Complaint, the Company provides the following additional risk factor, which supplements the risk factors previously disclosed by the Company in Part I, Item 1A, Risk Factors, of the 2020 10-K.

***We are the subject of an SEC Complaint, which could divert management's focus, result in substantial litigation expenses and have an adverse impact on our business, reputation, financial condition, results of operations or stock price.***

We are currently subject to an SEC Complaint. Refer to Note 17 to our Consolidated Financial Statements and Part II, Item 1 of this Quarterly Report for additional information regarding this specific matter. We may be subject to additional investigations, arbitration proceedings, audits, regulatory inquiries and similar actions, including matters related to intellectual property, employment, securities laws, disclosures, tax, accounting, class action and product liability, as well as regulatory and other claims related to our business and our industry, which we refer to collectively as legal proceedings. We cannot predict the outcome of any particular proceeding, or whether ongoing investigations, will be resolved favorably or ultimately result in charges or material damages, fines or other penalties, enforcement actions, bars against serving as an officer or director, or practicing before the SEC, or civil or criminal proceedings against us or members of our senior management.

Legal proceedings in general, and securities and class action litigation and regulatory investigations in particular, can be expensive and disruptive. Our insurance may not cover all claims that may be asserted against us, and we are unable to predict how long the legal proceedings to which we are currently subject will continue. An unfavorable outcome of any legal proceeding may have an adverse impact on our business, financial condition and results of operations or our stock price. Any proceeding could negatively impact our reputation among our stakeholders. Furthermore, publicity surrounding ongoing legal proceedings, even if resolved favorably for us, could result in additional legal proceedings against us, as well as damage our image.

***We may not be able to maintain compliance with the continued listing requirements of The Nasdaq Global Market.***

Our common stock is listed on the Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least $1.00 per share. If we fail to continue to meet all applicable continued listing requirements for The Nasdaq Global Market in the future and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock, our ability to obtain financing to repay debt, and fund our operations.

On April 13, 2022, we received a notice from The NASDAQ Stock Market (“Nasdaq”) that we did not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Rule”) that requires a Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The notice did not have any immediate effect on the listing of our common stock on the Nasdaq Capital Market and we had 45 calendar days from the date of the notice to submit a plan to Nasdaq to regain compliance with Nasdaq’s continued listing rules. We submitted such a plan on May 31, 2022, wherein we discussed the GeoTraq sale (see Note 25) and how that placed the Company back into compliance with the Rule. As of the filing date, we have received no further communication on the matter.

Filed Apr 25, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-014500. Last ingested by Listed: Nov 12, 2026, 17:09 ET. No prices; not investment advice.
